citalopram has been researched along with Anhedonia in 12 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Anhedonia: Inability to experience pleasure due to impairment or dysfunction of normal psychological and neurobiological mechanisms. It is a symptom of many PSYCHOTIC DISORDERS (e.g., DEPRESSIVE DISORDER, MAJOR; and SCHIZOPHRENIA).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Eighty-seven participants in the first Canadian Biomarker Integration Network in Depression (CAN-BIND-1) protocol received 8 weeks of open-label escitalopram." | 7.96 | Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. ( Arnott, SR; Ceniti, AK; Davis, AD; Downar, J; Dunlop, K; Foster, JA; Frey, BN; Harris, JK; Hassel, S; Kennedy, SH; Lam, RW; MacQueen, GM; Mansouri, F; Milev, R; Parikh, SV; Rizvi, SJ; Rotzinger, S; Schulze, L; Soares, CN; Strother, SC; Turecki, G; Uher, R; Zamyadi, M, 2020) |
| " The aim of the present study was to investigate whether stress-induced anhedonia could be prevented by treatments with escitalopram or novel herbal treatment (NHT) in an animal model of depression." | 7.85 | Escitalopram and NHT normalized stress-induced anhedonia and molecular neuroadaptations in a mouse model of depression. ( Barak, S; Burstein, O; Chen, G; Doron, R; Franko, M; Gale, E; Handelsman, A; Hirshler, Y; Motsan, S; Shamir, A; Simhon, O; Toledano, R, 2017) |
| " Alleviation of anhedonia was assessed in chronic mild stress model using sucrose preference test." | 4.12 | Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization. ( Abraham, R; Gagginapally, SR; Goura, V; Goyal, VK; Jasti, V; Jayarajan, P; Kallepalli, R; Medapati, RB; Mohammed, AR; Nirogi, R; Palacharla, VRC; Pandey, SK; Petlu, S; Subramanian, R; Tadiparthi, J; Thentu, JB, 2022) |
| " Eighty-seven participants in the first Canadian Biomarker Integration Network in Depression (CAN-BIND-1) protocol received 8 weeks of open-label escitalopram." | 3.96 | Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. ( Arnott, SR; Ceniti, AK; Davis, AD; Downar, J; Dunlop, K; Foster, JA; Frey, BN; Harris, JK; Hassel, S; Kennedy, SH; Lam, RW; MacQueen, GM; Mansouri, F; Milev, R; Parikh, SV; Rizvi, SJ; Rotzinger, S; Schulze, L; Soares, CN; Strother, SC; Turecki, G; Uher, R; Zamyadi, M, 2020) |
| " Change in reward sensitivity during the first 2 weeks of treatment was associated with improved depressive symptoms and anhedonia following 8 weeks of treatment with escitalopram." | 3.91 | Early change in reward and punishment sensitivity as a predictor of response to antidepressant treatment for major depressive disorder: a CAN-BIND-1 report. ( Allen, TA; Frey, BN; Kennedy, SH; Lam, RW; MacQueen, GM; Milev, R; Müller, DJ; Quilty, LC; Rizvi, SJ; Uher, R, 2019) |
| " The aim of the present study was to investigate whether stress-induced anhedonia could be prevented by treatments with escitalopram or novel herbal treatment (NHT) in an animal model of depression." | 3.85 | Escitalopram and NHT normalized stress-induced anhedonia and molecular neuroadaptations in a mouse model of depression. ( Barak, S; Burstein, O; Chen, G; Doron, R; Franko, M; Gale, E; Handelsman, A; Hirshler, Y; Motsan, S; Shamir, A; Simhon, O; Toledano, R, 2017) |
| "Late-life depression is associated with substantial heterogeneity in clinical presentation, disability, and response to antidepressant treatment." | 1.91 | Cognitive, Disability, and Treatment Outcome Implications of Symptom-Based Phenotyping in Late-Life Depression. ( Conway, C; Elson, D; Kang, H; Sudol, K; Szymkowicz, SM; Taylor, WD, 2023) |
| "Anhedonia is a core symptom of major depressive disorder (MDD)." | 1.46 | Patients with major depressive disorder exhibit reduced reward size coding in the striatum. ( Akiyama, Y; Awai, K; Fujii, Y; Ichikawa, N; Kaichi, Y; Minagawa, H; Mori, A; Okada, G; Okamoto, Y; Takaishi, Y; Takamura, M; Toki, S; Yamamoto, T; Yamawaki, S, 2017) |
| " We compared different phenotypes from the chronic mild stress (CMS) model of depression using chronic administration with two selective serotonin reuptake inhibitors (SSRIs), escitalopram and sertraline." | 1.38 | Vesicular signalling and immune modulation as hedonic fingerprints: proteomic profiling in the chronic mild stress depression model. ( Bak, S; Bisgaard, CF; Christensen, T; Enghild, JJ; Jensen, ON; Wiborg, O, 2012) |
| " Depression-related transcriptomic changes in gene expression profiles were investigated in laser-captured microdissected (LCM) rat hippocampal granular cell layers (GCL) using the chronic mild stress (CMS) rat model of depression and chronic administration of two selective serotonin reuptake inhibitors (SSRIs), escitalopram and sertraline." | 1.37 | Biomarkers of anhedonic-like behavior, antidepressant drug refraction, and stress resilience in a rat model of depression. ( Bisgaard, CF; Christensen, T; Wiborg, O, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 4 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Strekalova, T | 1 |
| Pavlov, D | 1 |
| Trofimov, A | 1 |
| Anthony, DC | 1 |
| Svistunov, A | 1 |
| Proshin, A | 1 |
| Umriukhin, A | 1 |
| Lyundup, A | 1 |
| Lesch, KP | 1 |
| Cespuglio, R | 1 |
| Nirogi, R | 1 |
| Abraham, R | 1 |
| Jayarajan, P | 1 |
| Goura, V | 1 |
| Kallepalli, R | 1 |
| Medapati, RB | 1 |
| Tadiparthi, J | 1 |
| Goyal, VK | 1 |
| Pandey, SK | 1 |
| Subramanian, R | 1 |
| Petlu, S | 1 |
| Thentu, JB | 1 |
| Palacharla, VRC | 1 |
| Gagginapally, SR | 1 |
| Mohammed, AR | 1 |
| Jasti, V | 1 |
| Sudol, K | 1 |
| Conway, C | 1 |
| Szymkowicz, SM | 1 |
| Elson, D | 1 |
| Kang, H | 1 |
| Taylor, WD | 1 |
| Dunlop, K | 1 |
| Rizvi, SJ | 2 |
| Kennedy, SH | 2 |
| Hassel, S | 1 |
| Strother, SC | 1 |
| Harris, JK | 1 |
| Zamyadi, M | 1 |
| Arnott, SR | 1 |
| Davis, AD | 1 |
| Mansouri, F | 1 |
| Schulze, L | 1 |
| Ceniti, AK | 1 |
| Lam, RW | 2 |
| Milev, R | 2 |
| Rotzinger, S | 1 |
| Foster, JA | 1 |
| Frey, BN | 2 |
| Parikh, SV | 1 |
| Soares, CN | 1 |
| Uher, R | 2 |
| Turecki, G | 1 |
| MacQueen, GM | 2 |
| Downar, J | 1 |
| Takamura, M | 1 |
| Okamoto, Y | 1 |
| Okada, G | 1 |
| Toki, S | 1 |
| Yamamoto, T | 1 |
| Ichikawa, N | 1 |
| Mori, A | 1 |
| Minagawa, H | 1 |
| Takaishi, Y | 1 |
| Fujii, Y | 1 |
| Kaichi, Y | 1 |
| Akiyama, Y | 1 |
| Awai, K | 1 |
| Yamawaki, S | 1 |
| Burstein, O | 1 |
| Franko, M | 1 |
| Gale, E | 1 |
| Handelsman, A | 1 |
| Barak, S | 1 |
| Motsan, S | 1 |
| Shamir, A | 1 |
| Toledano, R | 1 |
| Simhon, O | 1 |
| Hirshler, Y | 1 |
| Chen, G | 1 |
| Doron, R | 1 |
| Allen, TA | 1 |
| Müller, DJ | 1 |
| Quilty, LC | 1 |
| Alexander, L | 1 |
| Gaskin, PLR | 1 |
| Sawiak, SJ | 1 |
| Fryer, TD | 1 |
| Hong, YT | 1 |
| Cockcroft, GJ | 1 |
| Clarke, HF | 1 |
| Roberts, AC | 1 |
| Levada, OA | 1 |
| Troyan, AS | 1 |
| Christensen, T | 2 |
| Bisgaard, CF | 2 |
| Wiborg, O | 2 |
| Liu, R | 1 |
| Dang, W | 1 |
| Jianting, M | 1 |
| Su, C | 1 |
| Wang, H | 1 |
| Chen, Y | 1 |
| Tan, Q | 1 |
| Bak, S | 1 |
| Jensen, ON | 1 |
| Enghild, JJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)[NCT05017311] | Phase 4 | 400 participants (Anticipated) | Interventional | 2023-01-20 | Recruiting | ||
| Integrated Biological Markers for the Prediction of Treatment Response in Depression[NCT01655706] | Phase 3 | 211 participants (Actual) | Interventional | 2012-04-23 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for citalopram and Anhedonia
| Article | Year |
|---|---|
Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram.
Topics: Adult; Anhedonia; Antidepressive Agents; Citalopram; Cognition; Cognitive Dysfunction; Depressive Di | 2019 |
11 other studies available for citalopram and Anhedonia
| Article | Year |
|---|---|
Hippocampal Over-Expression of Cyclooxygenase-2 (COX-2) Is Associated with Susceptibility to Stress-Induced Anhedonia in Mice.
Topics: Anhedonia; Animals; Antidepressive Agents; Celecoxib; Citalopram; Cyclooxygenase 2; Depression; Hind | 2022 |
Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization.
Topics: Anhedonia; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Citalopram; Depressive | 2022 |
Cognitive, Disability, and Treatment Outcome Implications of Symptom-Based Phenotyping in Late-Life Depression.
Topics: Aged; Anhedonia; Citalopram; Cognition; Depression; Escitalopram; Fatigue; Humans; Sleep Initiation | 2023 |
Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report.
Topics: Anhedonia; Biomarkers; Canada; Citalopram; Depression; Depressive Disorder, Major; Humans; Magnetic | 2020 |
Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report.
Topics: Anhedonia; Biomarkers; Canada; Citalopram; Depression; Depressive Disorder, Major; Humans; Magnetic | 2020 |
Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report.
Topics: Anhedonia; Biomarkers; Canada; Citalopram; Depression; Depressive Disorder, Major; Humans; Magnetic | 2020 |
Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report.
Topics: Anhedonia; Biomarkers; Canada; Citalopram; Depression; Depressive Disorder, Major; Humans; Magnetic | 2020 |
Patients with major depressive disorder exhibit reduced reward size coding in the striatum.
Topics: Adult; Anhedonia; Anticipation, Psychological; Antidepressive Agents, Second-Generation; Brain Mappi | 2017 |
Escitalopram and NHT normalized stress-induced anhedonia and molecular neuroadaptations in a mouse model of depression.
Topics: Anhedonia; Animals; Antidepressive Agents, Second-Generation; Brain-Derived Neurotrophic Factor; Cit | 2017 |
Early change in reward and punishment sensitivity as a predictor of response to antidepressant treatment for major depressive disorder: a CAN-BIND-1 report.
Topics: Adolescent; Adult; Anhedonia; Antidepressive Agents; Aripiprazole; Citalopram; Depressive Disorder, | 2019 |
Fractionating Blunted Reward Processing Characteristic of Anhedonia by Over-Activating Primate Subgenual Anterior Cingulate Cortex.
Topics: Anhedonia; Animals; Blood Pressure; Callithrix; Citalopram; Conditioning, Classical; Discrimination, | 2019 |
Biomarkers of anhedonic-like behavior, antidepressant drug refraction, and stress resilience in a rat model of depression.
Topics: Anhedonia; Animals; Biomarkers; Citalopram; Depression; Disease Models, Animal; Drug Resistance; Eat | 2011 |
Citalopram alleviates chronic stress induced depression-like behaviors in rats by activating GSK3β signaling in dorsal hippocampus.
Topics: Anhedonia; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; beta Catenin; Blottin | 2012 |
Vesicular signalling and immune modulation as hedonic fingerprints: proteomic profiling in the chronic mild stress depression model.
Topics: Anhedonia; Animals; Citalopram; Depression; Disease Models, Animal; Hippocampus; Immune System; Lase | 2012 |